Two Drug Studies In DMD Remain
Open
The Cooperative International Neuromuscular Research Group
(CINRG), based at Children’s National Medical Center in
Washington, has space remaining in two clinical trials in children
with Duchenne muscular dystrophy (DMD).
Recruitment for participants in a study of moderate-dose, daily prednisone versus high-dose, weekly prednisone in boys
4 to 10 years old and able to walk unassisted has been extended
until approximately December at multiple sites throughout the
United States and elsewhere. (See www.mda.org/research/view_ctrial.aspx?id=95)
The trial is supported in part by MDA. Contact Lauren Morgenroth,
project manager, at (412) 383-7207 or morgenrothl@upmc.edu.
Recruitment for a study of pentoxifylline, an anti-inflammatory
drug that may also reduce scar tissue formation in muscles,
remains open, probably through mid-summer, at several U.S. sites.
(See www.mda.org/research/view_ctrial.aspx?id=131)
The investigators are seeking boys who are 4 to 7 years old
and have never taken steroids. Contact Angela Zimmerman, project
manager, at (202) 884-4110 or azimmerman@cnmcresearch.org. | 
